Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Natera reported a quarterly loss of $0.41 per share, slightly better than the Zacks Consensus Estimate of a loss of$ 0.42, and improved from a loss of $0.64 per share a year ago, indicating a 35.9% year-over-year improvement [1] - The company achieved revenues of$ 476.06 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.88% and showing a significant increase from $311.11 million in the same quarter last year, representing a 52.9% year-over-year growth [2] - Natera has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$ 0.38 on revenues of $426.69 million, while for the current fiscal year, the estimate is -$ 1.25 on revenues of $1.79 billion [7] - The estimate revisions trend for Natera is favorable, leading to a Zacks Rank 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6] Industry Context - The Medical Services industry, to which Natera belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be a useful tool for investors [5]